Summit Partners Public Asset Management LLC Buys 284,066 Shares of Natera, Inc. $NTRA

Summit Partners Public Asset Management LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 229.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 407,653 shares of the medical research company’s stock after purchasing an additional 284,066 shares during the quarter. Natera comprises about 1.9% of Summit Partners Public Asset Management LLC’s portfolio, making the stock its 7th biggest position. Summit Partners Public Asset Management LLC’s holdings in Natera were worth $93,389,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Horizon Investments LLC raised its stake in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its stake in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares in the last quarter. Savvy Advisors Inc. raised its stake in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH raised its stake in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH raised its stake in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after acquiring an additional 62 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on NTRA shares. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, Royal Bank Of Canada started coverage on shares of Natera in a research note on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $256.53.

Insiders Place Their Bets

In other news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the sale, the director owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Fesko sold 1,438 shares of Natera stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total transaction of $291,683.92. Following the completion of the sale, the insider directly owned 185,782 shares in the company, valued at approximately $37,684,020.88. The trade was a 0.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 159,378 shares of company stock valued at $34,640,860. Corporate insiders own 5.05% of the company’s stock.

Natera Stock Up 1.4%

Shares of NASDAQ:NTRA opened at $220.11 on Wednesday. The company has a market cap of $31.52 billion, a price-to-earnings ratio of -135.04 and a beta of 1.56. The firm’s 50-day simple moving average is $206.92 and its 200-day simple moving average is $215.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.